Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: A model for assessing causal association in pharmacovigilance

Drug Safety

Volumn 30, Issue 4, 2007, Pages 333-346

  Perrio, Michael ^a   Voss, Simon ^b   Shakir, Saad A W ^a,c  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; DILTIAZEM; DOFETILIDE; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; PAROXETINE; POTASSIUM CHANNEL HERG; SPARFLOXACIN; TERFENADINE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BRADFORD HILL CRITERIA; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EMBASE; HEART ARRHYTHMIA; HUMAN; MEDLINE; NONHUMAN; PRIORITY JOURNAL; PUBLICATION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SYNCOPE; SYSTEMATIC REVIEW; TACHYCARDIA; TORSADE DES POINTES;

EID: 34247193634     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730040-00006     Document Type: Article

References (117)

1. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300
2. Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf 2002; 25 (6): 467-71
3. Shakir SAW. Causality and correlation in pharmacovigilance. In: Talbot J, Waller P, editors. Stephens' Detection of New Adverse Drug Reactions. 5th ed. Chichester: John Wiley & Sons Ltd, 2003: 329-43
4. Dear Health Professional letter. Suspension of cisapride (Prepulsid) licences: product withdrawal [online]. Available from URL: http://www.mhra.gov. uk/home/groups/pl-p/documents/drugsafetymessage/con019561.pdf [Accessed 2006 Aug 1]
5. Guo JJ, Curkendall S, Jones JK, et al. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003; 12 (4): 295-301
6. Weatherby LB, Nordstrom BL, Fife D, et al. The impact of wording in "Dear Doctor" letters and in black box labels. Clin Pharmacol Ther 2002; 72 (6): 735-42
7. De-Bruin ML, Panneman M-JM, Leufkens H-GM, et al. Use of cisapride with contraindicated drugs in the Netherlands. Ann Pharmacother 2002; 36 (2): 338-43
8. Jones JK, Fife D, Curkendall S, et al. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001; 283 (13): 1607-9
9. Weatherby LB, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Saf 2001; 10 (3): 211-8
10. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000; 284 (23): 3036-9
11. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003; 89 (11): 1362-72
12. Moss AJ. The QT interval and torsade de pointes. Drug Saf 1999; 21 Suppl. 1: 5-10
13. Tan HL, Hou CJ, Lauer MR, et al. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995; 122 (9): 701-14
14. Feinstein AR. Scientific standards vs. statistical associations and biologic logic in the analysis of causation. Clin Pharmacol Ther 1979; 25 (4): 481-92
15. US Department of Health EaW. Smoking and health. Public health service publication no. 1103. Washington. 1964 [online]. Available from URL: http://www.surgeongeneral.gov/ library/reports.htm [Accessed 2006 Aug 1]
16. Enger C, Cali C, Walker AM. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf 2002; 11 (6): 477-86
17. Walker AM, Szneke P, Weatherby LB, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999; 107 (4): 356-62
18. Inman W, Kubota K. Tachycardia during cisapride treatment [letter]. BMJ 1992; 305 (6860): 1019
19. Liehr H, Schmidt R. A German drug-monitoring study in general practice patients receiving cisapride for functional dyspepsia. Scand J Gastroenterol 1993; 195: 54-9
20. Tooley P-JH, Vervaet P, Wager E. Cardiac arrhythmias reported during treatment with cisapride. Pharmacoepidemiol Drug Saf 1999; 8 (1): 57-8
21. Wager E, Tooley P-JH, Pearce GL, et al. A comparison of two cohort studies evaluating the safety of cisapride: prescription-event monitoring and a large phase IV study. Eur J Clin Pharmacol 1997; 52 (2): 87-94
22. De-Bruin ML, Hoes AW, Leufkens H-GM. QTc-prolonging drugs and hospitalizations for cardiac arrhythmias. Am J Cardiol 2003; 91 (1): 59-62
23. Straus S-MJ-M, Sturkenboom M-CJ-M, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005; 26 (19): 2007-12
24. Layton D, Key C, Shakir SAW. Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future. Pharmacoepidemiol Drug Saf 2003; 12 (1): 31-40
25. Wysowski DK, Corken A, Gallo Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96 (6): 1698-703
26. Committee for Proprietary Medicinal Products (CPMP). Opinion following an article 31 referral: cisapride. The European Agency for the Evaluation of Medicinal Products, 2002 [online]. Available from URL: http://www.emea.eu.int/ pdfs/ human/referral/cisapride/2484402en.pdf [Accessed 2006 Aug 1]
27. Ahmad RS, Wolfe SM. Cisapride and torsades de pointes. Lancet 1995; 345: 508
28. Barbey JT, Lazzara R, Zipes DP. Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 2002; 7 (2): 65-76
29. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335 (4): 290-1
30. Olsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992; 305 (6856): 748-9
31. Bran S, Murray WA, Hirsch IB, et al. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995; 155 (7): 765-8
32. Lewin MB, Bryant RM, Fenrich AL, et al. Cisapride-induced long QT interval. J Pediatr 1996; 128 (2): 279-81
33. Jenkins IR, Gibson J. Cisapride, erythromycin and arrhythmia. Anaesth Intensive Care 1996; 24 (6): 728
34. Pettignano R, Chambliss CR, Darsey E, et al. Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support. Crit Care Med 1996; 24 (7): 1268-71
35. Tierney MG, Uhthoff TL, Kravcik S, et al. Potential cisapride- erythromycin interaction. Can J Clin Pharmacol 1997; 4 (2): 82-4
36. Bedu A, Lupoglazoff JM, Faure C, et al. Cisapride high dosage and long QT interval. J Pediatr 1997; 130 (1): 164
37. Hanson R, Browne G, Fasher B, et al. Cisapride-induced prolonged QT interval: too much of a good thing! J Pediatr 1997; 130 (1): 164-6
38. Bernardini S, Semama DS, Huet F, et al. Effects of cisapride on QTC interval in neonates. Arch Dis Child Fetal Neonatal Ed 1997; 77 (3): F241-3
39. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997; 30 (3): 437-9
40. Nolan MA, Matos J, Wallach I, et al. Ventricular tachycardia associated with cisapride-related prolongation of the QT interval. J Noninvasive Cardiol 1998; 2 (4): 33-5
41. Vitola J, Vukanovic J, Roden DM. Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol 1998; 9 (10): 1109-13
42. Thomas AR, Chan LN, Bauman JL, et al. Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy 1998; 18 (2I): 381-5
43. Gray VS. Syncopal episodes associated with cisapride and concurrent drugs. Ann Pharmacother 1998; 32 (6): 648-51
44. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999; 33 (1): 22-6
45. Ng KS, Tham LS, Tan HH, et al. Cisapride and torsades de pointes in a pacemaker patient. Pacing Clinical Electrophysiol 2000; 23 (1): 130-2
46. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11 (6): 691-6
47. Kyrmizakis DE, Chimona TS, Kanoupakis EM, et al. QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin. Am J Otolaryngol 2002; 23 (5): 303-7
48. Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002; 106 (10): 1269-74
49. Hoover CA, Carmichael JK, Nolan PE Jr, et al. Cardiac arrest associated with combination cisapride and itraconazole. J Cardiovasc Pharmacol Ther 1996; 1 (3): 255-8
50. Michalets EL, Williams CR. Drug interactions with cisapride. Clinical implications. Clin Pharmacokinet 2000; 39 (1): 49-75
51. Bateman DN. The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur J Clin Pharmacol 1986; 30 (2): 205-8
52. Francois I, De Nutte N. Nonulcer dyspepsia: effect of the gastrointestinal prokinetic drug cisapride. Curr Ther Res 1987; 41 (6): 891-8
53. Usha-Rani P, Naidu M-UR, Ramesh Kumar T, et al. Tachycardia during cisapride treatment. Indian J Pharmacol 1994; 26 (3): 233-4
54. Zix JA, Geerdes-Fenge HF, Rau M, et al. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother 1997; 41 (8): 1668-72
55. Van-Haarst AD, Klooster G-AE, Van-Gerven J-MA, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998; 64 (5): 542-6
56. Hill SL, Evangelista J-AK, Pizzi AM, et al. Proarrhythmia associated with cisapride in children. Pediatrics 1998; 101 (6): 1053-6
57. Kivisto KT, Lilja JJ, Backman JT, et al. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 1999; 66 (5): 448-53
58. Khoshoo V, Edell D, Clarke R. Effect of cisapride on the QT interval in infants with gastroesophageal reflux. Pediatrics 2000; 105 (2): E24
59. Laine K, Forsstrom J, Gronroos P, et al. Frequency and clinical outcome of potentially harmful drug metabolic interactions in patients hospitalized on internal and pulmonary medicine wards: focus on warfarin and cisapride. Ther Drug Monit 2000; 22 (5): 503-9
60. Wang SH, Lin CY, Huang TY, et al. QT interval effects of cisapride in the clinical setting. Int J Cardiol 2001; 80 (2-3): 179-83
61. Russell JL. Relatively low doses of cisapride in the treatment of nausea in patients treated with venlafaxine for treatment of refractory depression. J Clin Psychopharmacol 1996; 16 (1): 35-7
62. Zhou H, Herron J, Liu Y, et al. A new rapidly disintegrating formulation of cisapride is bioequivalent to standard cisapride tablets in the elderly. Clin Drug Invest 1997; 14 (6): 487-93
63. Levine A, Fogelman R, Sirota L, et al. QT interval in children and infants receiving cisapride. Pediatrics 1998; 101 (3): E9
64. Ferron GM, Paul JC, Fruncillo RJ, et al. Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. J Clin Pharmacol 1999; 39 (9): 945-50
65. Ramirez-Mayans J, Garrido-Garcia LM, Huerta Tecanhuey A, et al. Cisapride and QTc interval in children. Pediatrics 2000; 106 (5I): 1028-30
66. Zhao Q, Wojcik MA, Parier JL, et al. Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers. Pharmacotherapy 2001; 21 (2): 149-57
67. Levy J, Hayes C, Kern J, et al. Does cisapride influence cardiac rhythm? Results of a United States multicenter, double-blind, placebo-controlled pediatric study. J Pediatr Gastroenterol Nutr 2001; 32 (4): 458-63
68. Offman EM, Freeman DJ, Dresser GK, et al. Red wine-cisapride interaction: Comparison with grapefruit juice. Clin Pharmacol Ther 2001; 70 (1): 17-23
69. Camberos A, Cymerman J, DiFronzo LA, et al. The effect of cisapride on the success of early feeding after elective open colon resection. Am Surg 2002; 68 (12): 1093-6
70. Alderman J. Coadministration of sertraline with cisapride or pimozide: an open- label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. Clin Ther 2005; 27 (7): 1050-63
71. Benatar A, Feenstra A, Decraene T, et al. Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography. Pediatrics 2000; 106 (6): E85
72. Abell TL, Adl D, Alkheshen M, et al. Lack of correlation of cisapride levels with ECG changes [abstract]. Am J Gastroenterol 1999; 94: 2756A
73. Rothman KJ, Greenland S. Causation and causal inference. In: Rothman KJ, Greenland S, editors. Modern epidemiology. Philadelphia (PA): Lippencott-Raven, 1998: 7-28
74. Rampe D, Roy ML, Dennis A, et al. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417 (1): 28-32
75. Mohammad S, Zhou Z, Gong Q, et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273 (5 Pt 2): H2534-8
76. Bedford TA, Rowbotham DJ. Cisapride. Drug interactions of clinical significance. Drug Saf 1996; 15 (3): 167-75
77. Cisapride drug interactions can be fatal. Drugs and Therapy Perspectives 1997; 9 (7): 11-3
78. Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000; 39 (4): 295-309
79. Chen J, Seebohm G, Sanguinetti MC. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci U S A 2002; 99 (19): 12461-6
80. Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97 (2): 204-10
81. Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. J Pharmacol Exp Ther 2001; 299 (3): 1007-12
82. Walker BD, Singleton CB, Bursill JA, et al. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol 1999; 128 (2): 444-50
83. Humphrey PPA, Bunce KT. Tachycardia during cisapride treatment. BMJ 1992; 305: 1019-20
84. Kaumann AJ. Do human atrial 5-HT4 receptors mediate arrhythmias? Trends Pharmacol Sci 1994; 15 (12): 451-5
85. Puisieux FL, Adamantidis MM, Dumotier BM, et al. Cisapride-induced prolongation of cardiac action potential and early after depolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996; 117 (7): 1377-9
86. Carlsson L, Amos GJ, Andersson B, et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Expl Ther 1997; 282 (1): 220-7
87. Kii Y, Ito T. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997; 29 (5): 670-5
88. Al-Wabel NA, Strauch SM, Keene BW, et al. Electrocardiographic and hemodynamic effects of cisapride alone and combined with erythromycin in anesthetized dogs. Cardiovasc Toxicol 2002; 2 (3): 195-207
89. Dumotier BM, Bastide M, Adamantidis MM. "Use-dependent" effects of cisapride on postrest action potentials in rabbit ventricular myocardium. Eur J Pharmacol 2001; 422 (1-3): 137-48
90. Di-Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003; 108 (8): 1027-33
91. Lin J, Guo J, Gang H, et al. Intracellular K(+) is required for the inactivation-induced high- affinity binding of cisapride to HERG channels. Mol Pharmacol 2005; 68 (3): 855-65
92. Kii Y, Nakatsuji K, Nose I, et al. Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats. Pharmacol Toxicol 2001; 89 (2): 96-103
93. Tamargo J. Drug-induced torsade de pointes: From molecular biology to bedside. Jpn J Pharmacol 2000; 83 (1): 1-19
94. Clancy CE, Kurokawa J, Tateyama M, et al. K(+) Channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Ann Rev Pharmacol Toxicol 2003; 43: 441-61
95. Paakkari I. Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 2002; 127 (1-3): 279-84
96. Tristani-Firouzi M, Chen J, Mitcheson JS, et al. Molecular biology of K(+) channels and their role in cardiac arrhythmias. Am J Med 2001; 110 (1): 50-9
97. Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94 (4): 817-23
98. Suessbrich H, Waldegger S, Lang F, et al. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor anatagonists terfenadine and astemizole. FEBS Lett 1996; 385 (1-2): 77-80
99. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80 (5): 795-803
100. Snyders DJ, Chaudhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 1996; 49 (6): 949-55
101. Council for International Organizations of Medical Science (CIOMS). Report of CIOMS Working Group IV. Benefit-risk balance for monitored drugs: evaluating safety signals. Geneva: WHO, 1998: 2
102. Walker DK. Use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol 2004; 58 (6): 601-8
103. Weed DL. Weak associations and biological plausibility, 2004. SRA Society for Risk Analysis 2004 annual meeting [online] Available from URL: http://birenheide.com/sra/2004AM/program/singlesession.php3?.sessid = T21 [Accessed 2006 Aug 1]
104. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. 2nd ed. New York: Churchill Livingstone, 2000
105. Clarke A, Deeks JJ, Shakir SAW. An assessment of the publicly disseminated evidence of safety used in the decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006; 29 (2): 175-81
106. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2006; 329: 44-7
107. CIOMS I suspect adverse reaction report form [online]. Available from URL: http://www.cioms.ch/cioms.pdf [Accessed 2006 Aug 1]
108. Food and Drug Administration. Reviewer guidance-evaluating the risk of drug exposure in human pregnancies [online]. Available from URL: http://www.fda.gov/cder/guidance/ 6777fnl.doc [Accessed 2006 Aug 1]
109. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Statement on evidence for association between consumption of alcoholic beverages and breast cancer: update of information published between 1995-1999 [online]. Available from URL: http://www.advisorybodies.doh.gov.uk/ pdfs/alcbrst.pdf [Accessed 2006 Aug 1]
110. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998; 90 (11): 814-23
111. Sears MR. Short-acting beta-agonist research: a perspective. Can Respir J 1997; 8 (5): 349-55
112. Spitzer WO. Bias versus causality: interpreting recent evidence of oral contraceptive studies. Am J Obstet Gynecol 1998; 179 (3 Pt 2): S43-50
113. Spitzer WO. Oral contraceptives and cardiovascular outcomes: cause or bias? Contraception 2000; 62 (2 Suppl.): 3-9S
114. Orlowski JP, Hanhan U, Fiallos M. Is aspirin a cause of Reye's syndrome? Authors' reply. Drug Saf 2006; 27 (1): 73-4
115. Weed DL, Gorelic LS. The practice of causal inference in cancer epidemiology. Cancer Epidemiol Biomarkers Prev 1996; 5 (4): 303-11
116. Parascandola M, Weed DL, Dasgupta A. Two surgeon generals' reports on smoking and cancer: a historical investigation. Emerg Themes Epidemiol 2006; 3: 1
117. Jick H. The discovery of drug-induced illness. N Engl J Med 1977; 296: 481-5